Evidence map›Paper›PMID 41536282›Full record

ArticleACS pharmacology & translational science2026

Protease-Activated Receptor 4 (PAR4)-Tethered Ligand Antagonists Demonstrate Thrombin Liability.

Emma M Webb, Jackson B Cassada, Heidi E Hamm

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Emma M WebbDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232-6600, United States.ORCID https://orcid.org/0000-0002-0281-3326
Jackson B CassadaDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232-6600, United States.
Heidi E HammDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232-6600, United States.

Funding

Cerebrovascular involvement in Alzheimer's Disease: PAR4 AntagonismR01AG068623 · NIA · VANDERBILT UNIVERSITY · PI HAMM, HEIDI E, MEILER, JENS · 2024 to 2025
$1.4M
NIA NIH HHS R01 AG068623
6 · The paper itself

Abstract

The Hamm laboratory recently published a cohort of PAR4 antagonists that were effective against the tethered ligand activation of PAR4. These compounds were generated from an ultralarge virtual screen using a homology model of PAR4. Upon further investigation, it appears the protease-activated receptor antagonists highlighted in this work have some thrombin liability. The Hamm laboratory further characterized the activity of these compounds using various methods, including a fluorescent thrombin activity assay, a chromogenic thrombin activity assay, and flow cytometry assays. We conclude that they do indeed antagonize PAR4, but thrombin is an additional target.

Indexed as

PharmacologyProtease-activated Receptor 4 (PAR4)ProteasesThrombin

Identifiers

PMID41536282
PMCPMC12797155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.